Correlation of serum PSA and Gleason score in Nigerian men with prostate cancer
- 69 Downloads
Prostate cancer is an important cause of morbidity and mortality worldwide. While the predisposing factors are not fully understood, African descent is an important risk factor, and prostate cancer has become the number-one cancer in Nigerian men. This was a retrospective study of the correlation between serum prostate specific antigen (PSA) and Gleason grade and score in patients of Nigerian descent.
Patients and Methods
The University College Hospital (UCH) Ibadan Cancer Registry was used to identify and quantify the incidence of prostate cancers occurring between 1998 and 2000. The histological slides of appropriate cases were reviewed to confirm the Gleason grade and score. The serum PSA values were retrieved from the patients' case notes and laboratory files. The data obtained were subjected to statistical analysis to look for associations and correlations.
The study included 67 men with prostate adenocarcinoma and PSA measurements who were diagnosed and treated at the UCH Ibadan between January 1998 and December 2000. There was a positive correlation between serum PSA and Gleason grade, as well as between serum PSA and Gleason score in our cohort of Nigerian African men with prostate cancer. PSA levels were significantly lower in patients with stage B disease than in patients with stage D disease.
Serum PSA is significantly higher in metastatic than in localized disease. Further studies are necessary to determine biomarkers that complement serum PSA and the Gleason grading system in the prognostication of prostate cancer in African patients.
KeywordsProstate cancer prostate specific antigen (PSA) Gleason score Nigeria
Unable to display preview. Download preview PDF.
- 1.http://www.cancer/org/downoads/STT/Global_Cancer_Facts_and_Figures_2007.pdfGoogle Scholar
- 3.Lubeck DP, Litwin MS, Henning JM, Stier DM, Mazonson P, Fisk R, et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 1996 Nov. 48(5):773–7.PubMedCrossRefGoogle Scholar
- 13.Kirby RS, Christmas TJ, Brawer M. Tumors markers in prostate cancer. In: Kirby RS, Christmas TJ, Brawer M, editors. Prostate cancer. 1st ed. Italy: Mosby; 1996. P.55–64.Google Scholar
- 15.Gleason DF. Histological grading and clinical staging of prostatic carciooma. In: Tannenbaum M, editor. Urologic pathology: The prostate. Philadelphia: Lea & Febiger; 1977. P.171–98.Google Scholar
- 16.D'Amico AV, McGovern FT, Church PA, Tempany CMC. The staging of prostate cancer. In: Kantoff PW, Wishnow KL, Loughlin KR, editors: Prostate cancer: A multiisciplinary guide. 1st ed. Massachusetts. Blackwell Scientific; 1997. P.41–56.Google Scholar
- 18.Gleason DF. Histological grading of prostatic carcinoma. In: Bostwick DG, editor. Pathology of the prostate. New Y York: Churchill Livingstone; 1990. P.83–93.Google Scholar
- 24.Iya D, Chanchani S, Belmonte J, Morris D, Glew RH, Van Der Jagt DJA. Prostate specific antigen in Africans: A study in Nigerian men. Nig J. Surg. Res. 2003;5(3):114–9.Google Scholar
- 25.The European Randomized study of Screening for Prostate Cancer(ERSPC). January 12, 2008;available at:http://www.erspc.org. Google Scholar
- 26.American Urological Association. Prostate cancer screening. 2006. http://www.urologyhealth.org/adult/index.cfmGoogle Scholar
- 28.Davidson P. and Gabbay J. Should mass screening for prostate cancer be introduced at the national level? WHO Regional Office for Europe Health Evidence Network (HEN), May 2004.Google Scholar